The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton have partnered to launch five new master’s and postgraduate ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its new Chief Executive Officer. Hopkins has more than 14 ...

Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge heart valve replacement ...

Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has received a positive recommendation from NICE for fourth-line use on the NHS in England and Wales. This new treatment is for ...

Purespring Therapeutics has raised £80m in an oversubscribed Series B financing round. Syncona Ltd, a leading life science investor, committed £19.9m as part of a syndicate led by Sofinnova, alongside ...

The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence ...

Biotech company moves forward with phase 2 trial for precision cancer surgery Copenhagen-based biotech company FluoGuide A/S has announced the submission of a Clinical Trial Application (CTA) for a ...

IRLAB Therapeutics AB has announced the successful completion of the first part of its Phase I clinical trial for IRL757, a drug candidate aimed at treating apathy in patients with Parkinson’s disease ...

In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23% at 24 months compared to enzalutamide in patients with metastatic ...

Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved Yuvanci (macitentan 10 mg and tadalafil 40 mg), a single tablet ...

ICON continues to celebrate its achievement at the 2024 Clinical Researcher of the Year Awards, where we were honoured to receive the ‘company of the year’ title in the International PharmaTimes ...